Key result
PRISM-guided ablation added to PVI cuts recurrent atrial arrhythmia risk by ~47% vs. PVI alone.
Why the study?
Catheter ablation for persistent AF has shown limited success, leading investigators to test whether adding PRISM mapping to identify AF drivers improves ablation results alongside PVI.
Does a PRISM-guided ablation approach added to pulmonary vein isolation reduce the recurrence of atrial arrhythmias in patients with persistent atrial fibrillation?
RCT (n=170)
Open-label
Simple randomization
Yes
Does a PRISM-guided ablation approach added to pulmonary vein isolation reduce the recurrence of atrial arrhythmias in patients with persistent atrial fibrillation?
Hazard Ratio: 0.53 (95% CI 0.33–0.85)
Absolute Event Rate: 70.6% vs 47.1%
p-value: p=0.003
Adding PRISM mapping-guided substrate ablation to conventional pulmonary vein isolation significantly reduces the recurrence of atrial fibrillation and atrial tachycardia in patients with persistent AF.
Supports PRISM mapping-guided ablation plus PVI in persistent AF; extends randomized evidence for driver-targeted substrate modification.
Importance: Catheter ablation for persistent atrial fibrillation (AF) has shown limited success. Objective: To determine whether AF drivers could be accurately identified by periodicity and similarity (PRISM) mapping ablation results for persistent AF when added to pulmonary vein isolation (PVI). Design, Setting, and Participants: This prospective randomized clinical trial was performed between June 1, 2019, and December 31, 2020, and included patients with persistent AF enrolled in 3 centers across Asia. Data were analyzed on October 1, 2022. Intervention: Patients were assigned to the PRISM-guided approach (group 1) or the conventional approach (group 2) at a 1:1 ratio. Main Outcomes and Measures: The primary outcome was freedom from AF or other atrial arrhythmia for longer than 30 seconds at 6 and 12 months. Results: A total of 170 patients (mean [SD] age, 62.0 [12.3] years; 136 men [80.0%]) were enrolled (85 patients in group 1 and 85 patients in group 2). More group 1 patients achieved freedom from AF at 12 months compared with group 2 patients (60 [70.6%] vs 40 [47.1%]). Multivariate analysis indicated that the PRISM-guided approach was associated with freedom from the recurrence of atrial arrhythmia (hazard ratio, 0.53 [95% CI, 0.33-0.85]). Conclusions and Relevance: The waveform similarity and recurrence pattern derived from high-density mapping might provide an improved guiding approach for ablation of persistent AF. Compared with the conventional procedure, this novel specific substrate ablation strategy reduced the frequency of recurrent AF and increased the likelihood of maintenance of sinus rhythm. Trial Registration: ClinicalTrials.gov Identifier: NCT05333952.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted an RCT in Persistent Atrial Fibrillation (n=170). PRISM-guided mapping and ablation vs. Conventional approach (Pulmonary vein isolation) was evaluated on Freedom from atrial fibrillation at 12 months (HR 0.53, 95% CI 0.33-0.85, p=0.003). Adding PRISM mapping-guided ablation to pulmonary vein isolation reduced the risk of recurrent atrial arrhythmia (HR 0.53) and increased 12-month freedom from atrial fibrillation to 70.6% compared to 47.1% with the conventional approach.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: